Ultragenyx (RARE) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $23.04
• Market Cap: $2.21B
• EPS: $-5.83
• 52-Week High: $43.22
• 52-Week Low: $18.41

Market Sentiment

Ultragenyx currently has a Bearish sentiment score of -0.17.

About Ultragenyx

Ultragenyx Pharmaceutical Inc. (RARE) is a leading biopharmaceutical firm dedicated to the advancement of innovative therapies for patients suffering from rare and ultra-rare genetic disorders. With its headquarters in Novato, California, the company is committed to addressing significant unmet medical needs through a robust pipeline of product candidates, which includes both gene therapy and enzyme replacement therapies. Ultragenyx employs a patient-centric approach, ensuring that the develo...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Ultragenyx and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does RARE pay dividends?

Ultragenyx (RARE) does not currently pay a regular dividend.

What is RARE's market cap?

Ultragenyx (RARE) has a market capitalization of $2.21B with a current stock price of $23.04.